For biotech companies, moving from preclinical to clinical trials often involves a shift from GMP-like to GMP/cGMP products, and finding the right vendor to develop those products is crucial. 

There are five areas companies should consider when working with a vendor to develop a product. Providing GMP vendors with a holistic view of the program, for example, ensures accurate timelines. This playbook explains how different aspects of a project can potentially impact the process for a biotech company moving into clinical trials, including:

• Determining quality grade: Understanding what is appropriate from a quality perspective is probably the biggest component 
• Investing in development: A client’s current project stage and the amount of development undertaken has a large impact on the manufacturing timeline 
• Evaluating technology transfer: Evaluating a biotech’s procedure — and understanding how to adapt to their equipment and scale of manufacturing — is critical

​